REG - Genflow Biosciences - Successful Placing and Subscription

Genflow BiosciencesAnnouncement

04/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240404:nRSD2131Ja&default-theme=true

RNS Number : 2131J  Genflow Biosciences PLC  04 April 2024

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS
ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE
INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS
SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

 

4 April 2024

 

Genflow Biosciences Plc

Successful Placing and Subscription To Raise £715,000, Grant of Warrants and
PDMR Notifications

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company")
which is rapidly becoming the major European exponent in the successful
development of therapeutic longevity solutions for  the prevention of
age-related diseases, is pleased to announce it has raised,  through its
broker Capital Plus Partners, £715,000 (before expenses) by way of a placing
and subscription of 57,200,000 new Ordinary Shares of 1.25 pence each (the
"Placing") (the "Placing Shares").

 

Further, each two Placing Shares will have one warrant attached,  exercisable
at 2 pence per share for three years from the date of issue. Holders of these
warrants will not, however, be able to exercise the same for a period of one
year from the date of grant.

 

Director Participation

 

All Directors participated in the Placing with the CEO Dr Eric Leire investing
£50,000 personally, the details of such participation are set out below.  No
Warrants are being issued to Directors.

 

Use of Proceeds

 

The net proceeds from the Placing will be used to continue development and
associated clinical trials. The near-term clinical trials are aimed at a
potential cure of the liver disease NASH which currently effects over 40
million people worldwide: in addition to conference participation and an
enhanced investor relations program.

 

Dr. Eric Leire, CEO of Genflow, commented: "We are delighted to have raised
this additional funding, noting the participation of Premier Miton, a
well-known UK institution. The success of this capital raise clearly reflects
the growing interest among UK institutional investors in the field of
longevity research. Interest amongst US institutional investors in the
Longevity sector is already well ahead of Europe, but we believe we have a
unique approach to address the growing issues of age-related diseases.

 

Broker Warrants

 

2,860,000 warrants were issued to Capital Plus Partners Ltd as part of its
broker fee, on the same terms set out above.

 

Application for Admission

 

The new ordinary shares to be issued pursuant to the Placing will
represent 19.56 per cent of the issued ordinary share capital of the Company
prior to the Placing. The Company will apply for admission of the Placing
Shares to listing on the standard listing segment of the Official List of
the FCA and to trading on the main market for listed securities of
the London Stock Exchange .The Placing Shares will rank pari passu in all
respects with the existing ordinary shares of £0.0003 in the capital of the
Company.  The Placing Shares are expected to be admitted for trading on or
around 9 April 2024.

 

Total Voting Rights

 

In accordance with the provision of the Disclosure Guidance and Transparency
Rules of the FCA ("DTRs"), the Company confirms that, following admission,
its issued share capital will comprise 349,706,618 Ordinary Shares, each of
which carries the right to vote, with no Ordinary Shares held in treasury.
This figure may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the DTRs

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

Contacts

 

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com
                      (mailto:Jonathan.Paterson@Harbor-access.com)

 

 Joint Corporate Brokers
 Clear Capital Markets          Capital Plus Partners Ltd
 Bob Roberts, +44 203 869 6080  Dominic Berger, +44 203 821 6167
                                Keith Swann, +44 203 821 6169
                                Jon Critchley, +44 203 821 6168

 

 

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating non-alcoholic steatohepatitis
(NASH), the most prevalent chronic liver disease for which there are no
effective treatments. Please visit www.genflowbio.com
(http://www.genflowbio.com)  and follow the Company on LinkedIn and
Twitter/X.

 

PDMR Notifications

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Eric Leire
 2.  Reason for notification
 a)  Position/Status                                              Chief Executive Officer
 b)  Initial notification/                                        Initial notification

     Amendment
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Genflow Biosciences Plc
 b)  LEI                                                          213800HVOFXRXVEGDN62
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of £0.0003 per share par value

Identification Code

                                                                  ISIN: GB00BP2C3V08
 b)  Nature of the transaction                                    Purchase of Ordinary Shares
 c)  Price(s) and volume(s)

Price(s)  Volume(s)
                                                                                 1.25p     4,000,000

 d)  Aggregated information                                       Single transaction as in 4 c) above

Price(s)  Volume(s)
     - Aggregated Volume                                          1.25p     4,000,000

     - Price
 e)  Date of the transaction                                      3 April 2024
 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 

d)

Aggregated information

 

- Aggregated Volume

 

- Price

Single transaction as in 4 c) above

 

 Price(s)  Volume(s)
 1.25p     4,000,000

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Outside a trading venue

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Tamara Joseph
 2.  Reason for notification
 a)  Position/Status                                              Non Executive Director
 b)  Initial notification/                                        Initial notification

     Amendment
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Genflow Biosciences Plc
 b)  LEI                                                          213800HVOFXRXVEGDN62
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of £0.0003 per share par value

Identification Code

                                                                  ISIN: GB00BP2C3V08
 b)  Nature of the transaction                                    Purchase of Ordinary Shares
 c)  Price(s) and volume(s)

Price(s)  Volume(s)
                                                                                 1.25p     800,000

 d)  Aggregated information                                       Single transaction as in 4 c) above

Price(s)  Volume(s)
     - Aggregated Volume                                          1.25p     800,000

     - Price
 e)  Date of the transaction                                      3 April 2024
 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 

d)

Aggregated information

 

- Aggregated Volume

 

- Price

Single transaction as in 4 c) above

 

 Price(s)  Volume(s)
 1.25p     800,000

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Outside a trading venue

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Yassine Bendiabdallah
 2.  Reason for notification
 a)  Position/Status                                              Non Executive Director
 b)  Initial notification/                                        Initial notification

     Amendment
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Genflow Biosciences Plc
 b)  LEI                                                          213800HVOFXRXVEGDN62
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of £0.0003 per share par value

Identification Code

                                                                  ISIN: GB00BP2C3V08
 b)  Nature of the transaction                                    Purchase of Ordinary Shares
 c)  Price(s) and volume(s)

Price(s)  Volume(s)
                                                                                 1.25p     800,000

 d)  Aggregated information                                       Single transaction as in 4 c) above

Price(s)  Volume(s)
     - Aggregated Volume                                          1.25p     800,000

     - Price
 e)  Date of the transaction                                      3 April 2024
 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 

d)

Aggregated information

 

- Aggregated Volume

 

- Price

Single transaction as in 4 c) above

 

 Price(s)  Volume(s)
 1.25p     800,000

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Outside a trading venue

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Peter King-Lewis
 2.  Reason for notification
 a)  Position/Status                                              Non Executive Director
 b)  Initial notification/                                        Initial notification

     Amendment
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Genflow Biosciences Plc
 b)  LEI                                                          213800HVOFXRXVEGDN62
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of £0.0003 per share par value

Identification Code

                                                                  ISIN: GB00BP2C3V08
 b)  Nature of the transaction                                    Purchase of Ordinary Shares
 c)  Price(s) and volume(s)

Price(s)  Volume(s)
                                                                                 1.25p     800,000

 d)  Aggregated information                                       Single transaction as in 4 c) above

Price(s)  Volume(s)
     - Aggregated Volume                                          1.25p     800,000

     - Price
 e)  Date of the transaction                                      3 April 2024
 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 

d)

Aggregated information

 

- Aggregated Volume

 

- Price

Single transaction as in 4 c) above

 

 Price(s)  Volume(s)
 1.25p     800,000

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Outside a trading venue

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Guy Charles Fanneau de la Horie
 2.  Reason for notification
 a)  Position/Status                                              Non Executive Director
 b)  Initial notification/                                        Initial notification

     Amendment
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Genflow Biosciences Plc
 b)  LEI                                                          213800HVOFXRXVEGDN62
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of £0.0003 per share par value

Identification Code

                                                                  ISIN: GB00BP2C3V08
 b)  Nature of the transaction                                    Purchase of Ordinary Shares
 c)  Price(s) and volume(s)

Price(s)  Volume(s)
                                                                                 1.25p     800,000

 d)  Aggregated information                                       Single transaction as in 4 c) above

Price(s)  Volume(s)
     - Aggregated Volume                                          1.25p     800,000

     - Price
 e)  Date of the transaction                                      3 April 2024
 f)  Place of the transaction                                     Outside a trading venue

 

 

 

 

d)

Aggregated information

 

- Aggregated Volume

 

- Price

Single transaction as in 4 c) above

 

 Price(s)  Volume(s)
 1.25p     800,000

e)

Date of the transaction

3 April 2024

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEXLFBZZLFBBB